At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Pfizer's decision is based on the totality of clinical data
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
The special Tele MANAS cell to serve as a dedicated mental health assistance helpline for all Armed Forces beneficiaries across country
Subscribe To Our Newsletter & Stay Updated
